tures yielded Citrobacter species at the National Taiwan University Hospital (Taipei), a major teaching hospital in Taiwan; this hospital had 1,200 beds before 1991 and 1,500 beds after 1991. The blood culture medium used to grow Citrobacter had been changed from trypticase soy broth containing sodium polyanetholesulfonate and modified Lombard-Dowell broth to the Bactec 6A broth and the Bactec 7A broth (Becton Dickinson, Sparks, MD) in 1987. Citrobacter species were identified according to standard laboratory methods. Antimicrobial susceptibility tests were done by means of the Kirby-Bauer disk diffusion method [8, 9] . Multidrug-resistance was defined as resistance in vitro to the extended-spectrum penicillins (ticarcillin, ticarcillinlclavulanate, and piperacillin) and the third-generation cephalosporins (cefotaxime, ceftazidime, ceftizoxime, ceftriaxone, and cefoperazone) [7] .
A patient was considered to have citrobacter bacteremia when this organism was isolated from blood cultures on at least one occasion. The primary site of infection was determined on the basis of a clinical picture that was consistent with the laboratory data and/or by a culture of tissue that was positive for a Citrobacter species. If none of these findings was present, the origin of the bacteremia was deemed unknown. Bacteremia was defined as nosocomial if infections were acquired during treatment at the study hospital, at other hospitals before transfer to the study hospital, or during out-patient clinic visits or emergency room visits. Otherwise, the bacteremia was considered to be community acquired.
The empirical treatment was considered appropriate if all organisms cultured were found to be susceptible to the drug(s) during in vitro susceptibility testing. Treatment was defined as delayed if no appropriate treatment was begun within 48 hours after blood for cultures was drawn. Septic shock was defined as the septic syndrome, with a systolic blood pressure of <90 mm Hg or a drop in the mean arterial pressure of >40 mm Hg from the baseline, in the absence of other causes of hypoten-em 1996; 23 (September) sion. Outcome was evaluated at discharge or 1 month after treatment was started. Death was considered bacteremia-related if patients died within 10 days of the report of positive culture results. Patients who died of other conditions and had obvious initial clinical responses after receiving antibiotic treatment were excluded from the study.
Statistical analysis was performed with use of the X 2 test and a two-tailed Fisher's exact test. The odds ratios and 95% confidence intervals were calculated at the same time. The logit estimators used a correction of 0.5 in every cell of those labels that contained a zero.
Results
From 1982 through 1994, 56 blood cultures for 45 patients yielded Citrobacter species, and these isolates accounted for 0.55% of the 10,263 blood isolates recovered at our hospital during this period. Twenty-two patients (48.9%) were male, and 23 patients (51.1%) were female. The ages ranged from 2 days to 86 years (median age, 60 years). Eight patients (17.8%) were < 18 years of age.
Of the 45 episodes of bacteremia, 21 occurred during the first 6.5 years of the study period (1.28 episodes per 10,000 patients discharged) and the remaining 24 episodes occurred in the second period (1.18 episodes per 10,000 patients discharged). No significant change in the incidence of citrobacter bacteremia was found during this 13-year period. Throughout the entire study period, recovery of Citrobacter isolates from blood appeared to be random, since the isolates were not clustered by season or in outbreaks. Twenty-three episodes (51.1%) were community acquired, and 22 (48.9%) were nosocomial.
Underlying diseases. The patients' underlying diseases are listed in table 1. Of those who had a malignancy, five had leukemia, and 16 had solid tumors (including 13 of intraabdominal origin). The number of cases of citrobacter bacteremia per 10,000 newly registered cancer patients in our hospital was 49.5 for those with acute leukemia, 37.8 for those with chronic leukemia, 6.3 for those with solid tumors, and 19.9 for those with intraabdominal tumors (table 1) . Eight patients had received chemotherapy, and five of them were neutropenic (neutrophil count, <500/mm 3 ) when citrobacter bacteremia developed.
Primary sites of infection. The primary sites of infection and the numbers of patients who presented with each are listed in table 1. Intraabdominal infections (23 patients) included hepatobiliary tree infections (19, including three with liver abscesses), peritonitis (three), and perianal abscess (one). Ofthese 23 patients, 20 (87%) had underlying intraabdominal lesions including hepatobiliary stones (10 patients), malignancy with biliary obstruction (nine), and pancreatitis (one). Citrobacter bacteremia of intraabdominal origin was often associated with underlying intraabdominal pathology.
Eight (88.9%) of nine patients with urinary tract infections had urinary tract abnormalities. These abnormalities included neurogenic bladder, retroperitonealfibrosis and hydronephrosis, chronic cystitis, cervical cancer and hydronephrosis, rectal cancer and hydronephrosis, rectal cancer with a uroanal fistula, transitional cell carcinoma, and benign prostate hypertrophy with urethral stricture. The bacteremias that originated from the urinary tract were also frequently associated with local lesions.
Five patients had pneumonia, which was associated (in order of frequency) with prematurity, congestive heart failure, lymphoma, colon cancer, and congenital heart disease with asplenism.
Ofthree patients who had soft tissue infections and/or wound infections, one had cellulitis at the irradiated site of nasopharyngeal carcinoma, and one had a skin ulcer caused by extravasation with vincristine. The other patient had chronic lymphocytic leukemia with cellulitis of the leg but no obvious cutaneous breakdown.
One patient had citrobacter bacteremia secondary to gouty arthritis, and one premature neonate had citrobacter meningitis.
Nineteen of 42 patients with identified origins of infection had Citrobacter species isolated from the primary sites of infection. The specimens included bile (four patients), liver abscess (two), gall bladder pus (two), discharge from peritoneal cavity (one), perianal abscess (one), urine (five), lung tissue (one), sputum (one), CSF (one), and wound discharge (one) (table 1).
Three (6.7%) of the 45 patients presented with signs of citrobacter sepsis that had no identifiable origin. Two of these patients were children; one had acute lymphocytic leukemia, and the other had chemotherapy-induced leukopenia. The third patient, a 56-year-old male, had idiopathic segmental axial dystonia and underwent intermittent urinary catheterization; however, the results of his urinalysis were normal.
Fifteen patients for whom a hepatobiliary origin of infection was documented had community-acquired bacteremia. Six of nine patients with urinary tract infections acquired the infections in the community; the other three had nosocomial infections, and all of them had undergone urinary tract manipulation in the hospital.
Initial clinical manifestations ofbacteremia. Fever was the most common initial manifestion of bacteremia in these patients. Thirty-nine (86.7%) of the 45 patients had fever, two had hypothermia, and four had normal temperatures. Thirty-five febrile patients (77.8%) had chills. Fifteen patients (33.3%) were hypotensive. Eight (18.2%) of 44 patients had altered mental status, and 13 (32.5%) of 40 had oliguria. Five (12.5%) of 40 had cough, and 26 (61.9%) of 42 had abdominal pain, ileus, and/ or gastrointestinal bleeding; of these patients, 12 had jaundice. Twenty-eight (65.1%) of 43 patients had leukocytosis (WBC count, > 1O,000/mm 3 ) , and five (11.4%) of 44 had neutropenia (neutrophil count, <500/mm 3 ) due to prior chemotherapy for cancer.
Complications. Among the 45 patients, the most frequent complication was septic shock, which was present in 15 (33.3%) of the patients. Liver dysfunction was present in 15 (33.3%) of the patients; respiratory failure, in 13 (28.9%); deteriorated mental status, in 12 (26.7%); renal dysfunction, in 11 (24.4%); and thrombocytopenia, in 7 (15.6%). 
* Includes bone and joint infection (n = 1), CNS infection (1), and wound and soft-tissue infection (3).
I All IS patients' infections originated in the hepatobiliary tract.
Bacteriology. Of the 45 episodes of citrobacter bacteremia, 18 (40%) were due to Cifrcundii, and seven (15.6%) were due to C diversus. The Citrobacter isolates were not identified to the species level in the remaining cases. C freundii was a more frequent cause of bacteremia than was C diversus among patients with infections of intraabdominal origin (table 1) .
Citrobacter was isolated in association with other bacteria (most frequently gram-negative bacilli) from 15 of the 45 patients.
Other concomitantly isolated bacteria included Escherichia coli (six patients), Klebsiella pneumoniae (four), Bacteroides species (three), Enterococcus species (three), Aeromonas hydrophila (two), Morganella morganii (two), and Proteus vulgaris (one).
Polymicrobial infection was more frequent in patients with an intraabdominal origin of infection (nine patients), a communityacquired infection (nine), or a malignancy (eight, including six with intraabdominal malignancies).
Antimicrobial susceptibilities. Antimicrobial susceptibility patterns were analyzed for 44 strains (these data were not available for one strain). Resistance to ampicillin, cefazolin, and cefamandole was common. However, almost all of the strains tested were susceptible to gentamicin (table 2).
The percentage of C freundii isolates that were resistant to ampicillin, cefazolin, cefamandole, and cefotaxime was higher than the percentage of C diversus isolates that were resistant to these drugs.
Treatment with first-or second-generation cephalosporins before the onset of bacteremia resulted in an increase in the rate of resistance to ampicillin, cefazolin, and cefamandole but not to cefotaxime. On the other hand, pretreatment with third-generation cephalosporins resulted in an increase in the rate of resistance to cefotaxime. Multidrug resistance was found in five strains and was associated significantly (P < .01) with pretreatment with third-generation cephalosporins. All four multidrug-resistant strains that were tested were susceptible to ciprofloxacin.
Treatment. Thirty-five patients received appropriate antibiotic treatment. Four patients did not receive appropriate treatment within 48 hours of the onset of bacteremia, and five did not receive any effective medical treatment. Two of these nine patients died of bacteremia. The appropriateness of the treatment one patient received could not be judged because the drug susceptibilities of his isolates were not determined.
The 45 patients received one or more of the following antibiotics: penicillins (two patients When compared with all other single-agent regimens, combination therapy was found to be more protective, although this difference was not significant (P = .11) ( Surgical procedures or drainage were performed in 10 patients.
Outcome. Fifteen (33.3%) of the 45 patients died. Six of these 15 patients died of causes other than bacteremia, although they responded well to treatment of bacteremia. One other patient died of hepatic failure that was associated with gastric cancer, and the bacteremia probably contributed to his death. Eight (17.8%) of the 45 patients died of bacteremia. Table 3 lists potential risk factors for death due to citrobacter bacteremia. The initial manifestations that were significant risk factors included pneumonia, altered mental status, hypothermia, and oliguria, and complications during the course of the illness that were significant included septic shock, further deterioration in mental status, hyperbilirubinemia, hypercreatinemia, and thrombocytopenia. Polymicrobial bacteremia and alcoholism were also associated with an increase in mortality, but this increase was not significant statistically.
Factors such as old age, cold weather, place of acquisition, the primary site and/or manifestation of the infection (except pneumonia), antibiotic resistance, the initial presence of hypotension, the leukocyte count, chemotherapy, previous invasive procedure, pretreatment, delayed treatment, or no treatment did not have significant influence on mortality. Appropriate treatment did not result in lower mortality. Although infection that originated in the urinary tract was associated with lower mortality, the difference was not significant. Surgical intervention and combination therapy were associated with a protective effect.
Discussion
Citrobacter species have been reported as a cause of many kinds of human infections [1, 6, 10-13], but bacteremia due to these organisms remains uncommon. The incidence of Citrobacter bacteremia among our patients was similar to that reported by Drelichman and Band [3] .
The urinary tract was the leading site of citrobacter infection in many previous reports [1 -3, 14] , including the two that described citrobacter bacteremia [2, 3] . However, in our series, intraabdominal tissues (mainly in hepatobiliary system) were the most common primary sites of infection in bacteremic patients. The reason that such sites predominated in our series was that a large portion of our patients had hepatobiliary stones (22.2%) and intraabdominal malignancies (28.8%). Hepatobiliary infection was the most frequent (82.6% ofpatients) intraabdominal infection due to Citrobacter species, which is consistent with the findings of Lew et al. [15] . We emphasize that enterococci, E. coli, and anaerobes still predominate among patients with the pancreatic and hepatobiliary cancer and intraabdominal abscesses [16] , and antimicrobial coverage for these organisms should be considered first.
According to previous reports [1 -3, 14] , most citrobacter infections have been hospital acquired. In our study, about onehalf of the cases (51.1%) were community acquired, a finding that may be due to the predominance of cases hepatobiliary infection (19) in our study. One large-scale study [17] showed that hospital-acquired cases ofbacteremia predominated among patients with infections that originated from any site other than the biliary tree and reproductive tract. Fifteen (78.9%) of the 19 patients with hepatobiliary infection in our study had community-acquired bacteremia.
In one previous report of citrobacter bacteremia in patients with cancer [2] , those with acute leukemia accounted for the highest number with bacteremia due to Citrobacter species alone (this number was 20 times higher than the number of patients with solid tumors and citrobacter bacteremia). Although patients with acute leukemia still had the highest rate of citrobacter bacteremia in our study, those with tumors of the abdominal cavity were also found to have a high incidence (10.7 cases per 10,000 newly registered patients) of the infection. Furthermore, the incidence among such patients was even higher if cases of polymicrobial bacteremia were included (19.9 cases per 10,000 newly registered patients). We emphasize the importance of underlying intraabdominal tumors in the development of Citrobacter bacteremia among our patients, since this observation has not been made previously. The incidence (33.3%) of bacteremia due to Citrobacter, in combination with other organisms, in our hospital is similar to that (35%-46.1 %) observed by other investigators [3, 15] and is higher than that for bacteremias due to all organisms (6%-17.8%) or bacteremias due to gram-negative organisms (4%-25%) [17] [18] [19] [20] [21] [22] [23] . Isolation of Citrobacter as a part of a mixed infection in the abdominal cavity was unexpectedly common (nine patients) in our study. These cases presumably represented the introduction of Citrobacter species that were already present in the patients' gastrointestinal tracts; this phenomenon has been mentioned in previous reports [1, 3] .
One other important finding in our study was that administration of a third-generation cephalosporin within 14 days before the onset of citrobacter bacteremia had a significant influence on the selection of cefotaxime-resistant strains (P = .005) and multidrug-resistant strains (P = .017). This finding confirmed the fact that multidrug-resistant organisms may emerge more rapidly when the third-generation cephalosporins are used routinely, as has been predicted by other investigators [7] . The difference between C. freundii and C. diversus in terms of susceptibility to the cephalosporins has been noted since the 1970s [2, [4] [5] [6] and has been confirmed again in this study of strains that cause bacteremia.
Combination therapy had a protective effect in our study. This benefit of combination therapy has been proposed by other authors [2, 7] . Samonis et al. [24] reported that imipenem, amikacin, and the new fluoroquinolones had good activity against Citrobacter species. Our results are compatible with their findings. Because the data are limited, we suggest the use of combination therapy for initial empirical treatment of citrobacter bacteremia, and the fluoroquinolones can be used for the treatment of episodes due to multidrug-resistant strains. However, further studies are needed to support this recommendation.
The overall mortality associated with citrobacter bacteremia was 33.3% in our series; this percentage is lower than that (48.3%) reported by Drelichman et al. in 1985 [3] . The mortality associated with citrobacter bacteremia is similar to that for bacteremia due to Klebsiella species (37%) [25] , Enterobacter species (20%) [7] , Proteus mirabilis (29.0%) [21] , and bacteremias due to gram-negative organisms (25%) [4] but higher than that associated with E. coli bacteremia (10%) [22] . In previous reports [2, 7, 19, [21] [22] [23] [25] [26] [27] , many risk factors including the two extremes of age, pneumonia, sources of bacteremia other than the urinary tract, alcoholism, diabetes mellitus, congestive heart failure, infection with a multidrug-resistant strain, inappropriate treatment, respiratory tract infection, polymicrobial bacteremia, nosocomial infection, chemotherapy-induced neutropenia, leukocytosis, septic shock, azotemia, hyperbilirubinemia, and thrombocytopenia have all been significantly associated with death due to gram-negative bacteremia. In our series pneumonia, altered mental status, oliguria, septic shock, deterioration in mental status, azotemia, hyperbilirubinemia, and thrombocytopenia were found to have a significant influence on mortality. The fact that other factors were not significant was probably due to the smaller number of cases in our study.
In conclusion, citrobacter bacteremia is uncommon and usually develops in patients with underlying diseases. In our series, about one-half of cases were community em 1996;23 (September) acquired. An intraabdominal site, rather than the urinary tract, was the leading primary site of citrobacter infection. Malignancy, especially in the intraabdominal organs, and hepatobiliary stones were the two most predominant underlying diseases.
Citrobacter species were more often isolated in our cases of polymicrobial bacteremia than were other gram-negative bacilli because of the predominance of primary infections at contaminated sites, especially the abdominal cavity. When a patient presents with citrobacter bacteremia, a thorough search for an intraabdominal lesion should be made. Multidrug resistance among Citrobacter species was found to be associated with administration of a third-generation cephalosporin before the onset of bacteremia.
Because the data are limited, we suggest that ciprofloxacin be considered the drug of choice for bacteremia due to these strains. Combination therapy with a ,B-Iactarn and an aminoglycoside are suggested as the initial empirical treatment because this combination was associated with a lower mortality rate in our study. Septic shock with organ failure was the most important poor prognostic factor, and the need for good supportive care for patients with this complication cannot be overemphasized.
